Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
- Authors
- Xu, Kevin Y; Mintz, Carrie M; Presnall, Ned; Bierut, Laura J; Grucza, Richard A
- Year
- 2022
- Journal
- JAMA network open
- PMID
- 35536575
- DOI
- 10.1001/jamanetworkopen.2022.11363
- PMCID
- PMC9092203
IMPORTANCE: Despite prevalent polysubstance use, treatment patterns and outcomes for individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUD) are understudied. OBJECTIVE: To evaluate the distribution of buprenorphine and naltrexone initiation among individuals with OUD with vs without cooccurring SUD and to assess the comparative effectiveness associated with buprenorphine and naltrexone against drug-related poisonings. DESIGN, SETTING, AND PARTICIPANTS: This observational comparative effectiveness study used insurance claims from 2011 to 2016 from the US IBM MarketScan databases to study initiation of medications for OUD (MOUD) among treatment-seeking individuals aged 12 to 64 years with a primary diagnosis of OUD. Cooccurring SUD was defined as SUD diagnosed concurrent with or in the 6 months prior to OUD treatment initiation. Treatment was codified as psychosocial treatment without MOUD or initiation or buprenorphine or naltrexone (including extended-release or oral). Methadone recipients were excluded from analysis. Data were analyzed from February 3, 2021, through February 26, 2022. EXPOSURES: MOUD. MAIN OUTCOMES AND MEASURES: Associations between cooccurring SUD diagnoses with treatment type were assessed with multivariable regression. The association of drug-related poisoning admissions with days covered with buprenorphine or naltrexone prescriptions vs days without prescriptions was assessed among MOUD initiators. Odds ratios from within-person fixed effects models were estimated as a function of MOUD and stratified by cooccurring SUDs. RESULTS: Among 179 280 individuals with OUD (mean [SD] age, 33.2 [11.0] years; 90 196 [50.5%] men), 102 930 (57.4%) received psychosocial treatment without MOUD. Across 47 488 individuals with cooccurring SUDs, 33 449 (70.4%) did not receive MOUD, whereas across 131 792 individuals without cooccurring SUDs, 69 481 (52.7%) did not receive MOUD. Cooccurring SUD was associated with decreased odds of initiating buprenorphine (risk ratio [RR], 0.55 [95% CI, 0.54-0.56]) but increased odds of initiating naltrexone (extended release: RR, 1.12 [95% CI, 1.05-1.20]; oral: RR, 1.95 [95% CI, 1.86-2.03]). Among 12 485 individuals initiating MOUD who experienced at least 1 drug-related poisoning during insurance enrollment, buprenorphine treatment days were associated with decreased poisonings compared with days without MOUD for individuals with cooccurring SUD (odds ratio [OR], 0.56 [95% CI, 0.48-0.65]) and individuals without cooccurring SUD (OR, 0.57 [95% CI, 0.53-0.63]), with comparable associations observed for extended-release naltrexone. No protective association was observed for oral naltrexone. CONCLUSIONS AND RELEVANCE: These findings suggest that individuals with OUD and polysubstance use were less likely to initiate buprenorphine and naltrexone than individuals without polysubstance use. Among individuals initiating MOUD, polysubstance use was associated with decreased buprenorphine and increased naltrexone initiation, despite buprenorphine's protective associations against drug-related poisoning.
Flowchart of Derivation of Analytic SampleOUD indicates opioid use disorder; SUD, substance use disorder.
Odds of Acute Drug-Related Poisonings Associated With OUD Treatment Days Compared With Nontreatment Days, Stratified by Any Substance Use Disorder (SUD) Diagnosis During the 6 Months Preceding Treatment InitiationOdds ratios were calculated among 12 485 individuals encompassing 7 095 568 person-days. ER indicates extended release.
No entities extracted from this document yet.
No uploaded files.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| Comer SD, Mogali S, Saccone PA, . Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013;38(12):2427-2438. doi:10.1038/npp.2013.14323736314PMC3799062 | — | — | — |
| Digiusto E, Shakeshaft A, Ritter A, O’Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99(4):450-460. doi:10.1111/j.1360-0443.2004.00654.x15049745 | — | — | — |
| Farrell M, Ward J, Mattick R, . Methadone maintenance treatment in opiate dependence: a review. BMJ. 1994;309(6960):997-1001. doi:10.1136/bmj.309.6960.9977950725PMC2541312 | — | — | — |
| Ford BR, Bart G, Grahan B, Shearer RD, Winkelman TNA. Associations between polysubstance use patterns and receipt of medications for opioid use disorder among adults in treatment for opioid use disorder. J Addict Med. 2021;15(2):159-162. doi:10.1097/ADM.000000000000072632868682PMC7969153 | — | — | — |
| Heikman PK, Muhonen LH, Ojanperä IA. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. BMC Psychiatry. 2017;17(1):245. doi:10.1186/s12888-017-1415-y28683783PMC5501578 | — | — | — |
| Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101(4):491-503. doi:10.1111/j.1360-0443.2006.01369.x16548929 | — | — | — |
| Kessler RC, Aguilar-Gaxiola S, Berglund PA, . Patterns and predictors of treatment seeking after onset of a substance use disorder. Arch Gen Psychiatry. 2001;58(11):1065-1071. doi:10.1001/archpsyc.58.11.106511695954 | — | — | — |
| Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1-8. doi:10.1016/j.drugalcdep.2015.12.02126832931 | — | — | — |
| Lagisetty P, Garpestad C, Larkin A, . Identifying individuals with opioid use disorder: validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse. Drug Alcohol Depend. 2021;221:108583. doi:10.1016/j.drugalcdep.2021.10858333662670PMC8409339 | — | — | — |
| Larochelle MR, Bernson D, Land T, . Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. doi:10.7326/M17-310729913516PMC6387681 | — | — | — |
| Lee JD, Nunes EV Jr, Novo P, . Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318. doi:10.1016/S0140-6736(17)32812-X29150198PMC5806119 | — | — | — |
| Lin LA, Bohnert ASB, Blow FC, . Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2021;116(1):96-104. doi:10.1111/add.1511632428386 | — | — | — |
| Lin LA, Saitz R. What will it take to stem the tide: understanding and addressing the needs of people with addiction involving multiple substances. J Addict Med. 2021;15(1):1-2. doi:10.1097/ADM.000000000000066732530886 | — | — | — |
| Luo X, Sorock GS. Analysis of recurrent event data under the case-crossover design with applications to elderly falls. Stat Med. 2008;27(15):2890-2901. doi:10.1002/sim.317118095315 | — | — | — |
| Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2019;170(11):821-822. doi:10.7326/L19-014531158866 | — | — | — |
| Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202-207. doi:10.15585/mmwr.mm7006a433571180PMC7877587 | — | — | — |
| Mintz CM, Presnall NJ, Xu KY, . An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. Drug Alcohol Depend. 2021;226:108886. doi:10.1016/j.drugalcdep.2021.10888634245997PMC8370094 | — | — | — |
| Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34-39. doi:10.1016/j.drugalcdep.2019.02.03131082666PMC6613830 | — | — | — |
| National Center for Injury Prevention and Control Division of Unintentional Injury Prevention. Prescription drug overdose data and statistics: guide to ICD-9-CM and ICD-10 codes related to poisoning and pain. Revised August 2013. Accessed April 5, 2022. https://stacks.cdc.gov/view/cdc/59394 | — | — | — |
| O’Neil G, Hulse G, Arnold-Reed D, . Naltrexone in treatment of amphetamines, cannabis, and benzodiazepines. Accessed April 5, 2022. https://nida.nih.gov/international/abstracts/naltrexone-in-treatment-amphetamines-cannabis-benzodiazepines | — | — | — |
| Roche DJO, Worley MJ, Courtney KE, . Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. Psychopharmacology (Berl). 2017;234(13):1997-2007. doi:10.1007/s00213-017-4607-828357460PMC5480611 | — | — | — |
| Spagnolo PA, Ramchandani VA, Schwandt ML, . Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients. Alcohol Clin Exp Res. 2014;38(12):3024-3032. doi:10.1111/acer.1258125581657PMC4293087 | — | — | — |
| Xu KY, Borodovsky JT, Presnall N, . Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis. Am J Psychiatry. 2021;178(7):651-659. doi:10.1176/appi.ajp.2020.2008117433653119PMC8286284 | — | — | — |
No papers in this knowledge base cite this source.
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Effects of repeated nalfurafine and VZTK35 treatments on fentanyl/cocaine mixture self-administration in a rat drug-vs.-food choice procedure. | St Onge CM et al. | — | 2026 | → |
| Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study. | Hurley RW et al. | — | 2026 | → |
| Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder. | Roy PJ et al. | — | 2026 | → |
| Patient Profiles of Buprenorphine Initiators in General Healthcare Settings: A Latent Class Approach. | Grucza RA et al. | — | 2026 | → |
| Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries. | Treitler P et al. | — | 2026 | → |
| Association Between Sex and Recent Pregnancy and Hepatitis C Virus Treatment in People With Opioid Use Disorder. | Cary CB et al. | — | 2025 | → |
| Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. | Flanagan Balawajder E et al. | — | 2025 | → |
| Blood pressure response to extended-release naltrexone in heroin and prescription opioid users and its implications for cardiovascular morbidity. | Shi Z et al. | — | 2025 | → |
| Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis. | Xu KY et al. | — | 2025 | → |
| Content analysis of perceptions of combined pharmacobehavioral treatment for American Indian people with opioid use disorder. | Nelson LA et al. | — | 2025 | → |
| Differences in the travel burden for care between rural and urban patients with opioid use disorder by insurance type. | Andrilla CHA et al. | — | 2025 | → |
| Evolution of the substance use landscape: Implications for contingency management. | Goodwin S et al. | — | 2025 | → |
| Polysubstance Use Is Not Synonymous With Poly Substance Use Disorder. | Xu KY et al. | — | 2025 | → |
| Receipt of medications for opioid use disorder among rural and urban veterans health administration patients. | Reynolds OC et al. | — | 2025 | → |
| Risk of self-harm and overdose after starting buprenorphine for opioid use disorder. | Simon GE et al. | — | 2025 | → |
| Substance-induced mental disorders and discontinuation of medication for opioid use disorder. | Tilhou AS et al. | — | 2025 | → |
| Contraceptive uptake in postpartum people with and without opioid use disorder and opioid use with co-occurring substance use. | Bello JK et al. | — | 2024 | → |
| Co-occurring substance use disorders among patients with opioid use disorder in rural primary care clinics. | Zhu Y et al. | — | 2024 | → |
| First-hand accounts of structural stigma toward people who use opioids on Reddit. | Eschliman EL et al. | — | 2024 | → |
| Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention. | Afshar M et al. | — | 2024 | → |
| Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims. | Xu KY et al. | — | 2024 | → |
| Endogenous opiates and behavior: 2022. | Bodnar RJ | — | 2023 | → |
| Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. | Cook RR et al. | — | 2023 | → |
| Impact of an intervention to implement provision of opioid use disorder medication among patients with and without co-occurring substance use disorders. | Frost MC et al. | — | 2023 | → |
| Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA). | Allen ST et al. | — | 2023 | → |
| Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care. | Busch AB et al. | — | 2023 | → |
| Postmortem toxicology findings from the Camden Opioid Research Initiative. | Kusic DM et al. | — | 2023 | → |
| The role of polysubstance use on criminal justice involvement in the United States. | Jones AA et al. | — | 2023 | → |